Journal article icon

Journal article

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

Abstract:

The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other b...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/ajg.2010.392

Authors


D'Haens, GR More by this author
Panaccione, R More by this author
Higgins, PD More by this author
Vermeire, S More by this author
Gassull, M More by this author
Expand authors...
Journal:
The American journal of gastroenterology
Volume:
106
Issue:
2
Pages:
199-213
Publication date:
2011-02-05
DOI:
EISSN:
1572-0241
ISSN:
0002-9270
URN:
uuid:c948a493-60c5-493f-847e-af509ee1cad3
Source identifiers:
112446
Local pid:
pubs:112446

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP